Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 1247 publications.

Copley-Merriman K, Doward L, Hawe E, Cope S. Clinical trial design, beyond the regulatory. Presentation to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Raza S, Heyes A, Leonard C, D'Souza V, Carney R, Mackie D, Gelinas D, Swijsen A. Analysis of the burden of illness, treatment, and health disparities in amyotrophic lateral sclerosis. Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Buck PM, Masaquel C. The most heavily managed drug categories on Part D formularies. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Liang Y, Salomonsen R, Colosia A, Nelsen SH, Khan S, Sandelin M. Interventions to improve adherence and persistence to oral medication: a targeted literature review. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Pladevall-Vila M, Ziemiecki R, Johannes CB, Khan AM, Mines D, Ebert N, Kovesdy CP, Thomsen RW, Baak BN, Garcia-Sempere A, Kanegae H, Coleman CI, Walsh M, Andersen IT, Bernal CR, Cabaninas CR, Christiansen CF, Farjat AE, Gay A, Gee P, Herings RMC, Hurtado I, Kashihara N, Kristensen FPB, Liu F, Okami S, Overbeek JA, Beest FJAP, Yamashita S, Yano Y, Layton JB, Vizcaya D, Oberprieler NG. Clinical profile and treatment patterns in individuals with type 2 diabetes and chronic kidney disease who initiate a GLP-1 receptor agonist: a multinational cohort study. Diabetes Ther. 2025 May;16(5):931-54. doi: 10.1007/s13300-025-01717-8

Stempniewicz N, Davenport E, Wang J, Sweeney C. Herpes zoster vaccination: primary care provider knowledge, attitudes, and practices. Hum Vaccin Immunother. 2025 Apr 18;21(1):2488093. doi: 10.1080/21645515.2025.2488093

Tamhankar MA, Raza S, Brutsaert E, Urdaniz E, Vainilovich Y, Heyes A, Gildea L, Sales-Sanz M. The burden of illness in thyroid eye disease: current state of the evidence. Front Ophthalmol. 2025 Apr 16;5. doi: 10.3389/fopht.2025.1565762

Horn EK, La EM, Bektas M, Khan S, Gerber SI. Disparities in respiratory syncytial virus risk factors, diagnosis, and outcomes in adults by race, ethnicity, and other social determinants of health in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Apr;25(4):459-71. doi: 10.1080/14737167.2024.2441867

Aguado J, Gutierrez L, Forns J, Vila Guilera J, Rothman KJ, Garcia-Albeniz X. Effect of different durations of treatment with antihypertensive drugs with anticholinergic effects on the risk of dementia: a target trial emulation study. Am J Epidemiol. 2025 Mar 4;194(3):691-8. doi: 10.1093/aje/kwae263

Khanji C, Nuabor W, Gould T, Kim HK, Barrows S, Herbel B, Njue A. Systematic literature review of outcomes associated with adherence to haemophilia drug therapy. Haemophilia. 2025 Mar;31(2):187-206. doi: 10.1111/hae.15153

Perrone RD, Garbinsky D, Nunna S, Gandhi HK, Fernandes AW, Burgos G, Olopoenia A, DeCongelio M, Maculaitis MC, Zhou X. Effectiveness of tolvaptan for autosomal dominant polycystic kidney disease in US clinical practice with comparison to historical control data. Kidney Med. 2025 Feb 27;7(5):100988. doi: 10.1016/j.xkme.2025.100988

Murillo ER, Mora JRM, Bachiller MM, Santiago LG, Braque NN, Bravo MO. Factors associated with low adherence to inhaled therapy in patients with chronic respiratory diseases: a cross-sectional study. BMC Pulm Med. 2025 Feb 27;25(1):94. doi: 10.1186/s12890-025-03563-7.

Weisel K, Mateos MV, Landgren O, Leleu X, Quach H, Bennett L, Talpes M, Majer I, Patel S, Usmani SZ. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with carfilzomib, dexamethasone, and daratumumab versus carflizomib and dexamethasone: an analysis of patient-reported outcomes from the phase 3 CANDOR trial. Clin Lymphoma Myeloma Leuk. 2025 Feb 19. doi: 10.1016/j.clml.2025.02.005

Hellwig K, Magyari M, MacDonald TM, Cesta CE, Wergeland S, Leinonen MK, Ornoy A, Vukusic S, Lauer A, Zhou X, Kawai A, Weinrib R, Arana A, Boumenna T. A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update1. Ther Adv Neurol Disord. 2025 Jan 27;18:175628642. doi: 10.1177/17562864241310996

Wright GC, Zueger PM, Copley-Merriman K, Khan S, Costello J, Krumbach A, Reddy P, Tanjinatus O, Wells AF. Health disparities in rheumatology in the United States. Open Access Rheumatol. 2025 Jan 9;17:1-12. doi: 10.2147/OARRR.S493457

Chebib FT, Dahl N, Zhou X, Garbinsky D, Wang J, Nunna S, Oberdhan D, Fernandes AW. Tolvaptan and autosomal dominant polycystic kidney disease progression in individuals aged 18–35 years: a pooled database analysis. Kidney Med. 2025 Jan;7(1):100935. doi: 10.1016/j.xkme.2024.100935

La EM, Bunniran S, Garbinsky D, Reynolds M, Schwab P, Poston S, Harrington L. Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States. Hum Vaccin Immunother. 2024 Dec 31;20(1):2303796. doi: 10.1080/21645515.2024.2303796

D'Souza V, Bhogal P, Njue A. Impact of the innovative licensing and access pathway (ILAP) designation on regulatory and health technology assessment (HTA) outcomes. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S312. doi: 10..1016/j.jval.2024.10.1623

Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg CN, Brown JR, Dave V, Downey C, Shillington AC, Katzenstein HM, Kirker M, Hanson S, Liu FX, Morris V, Bhanegaonkar A, Sonpavde GP. Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the Real-world US PATRIOT-II Study. Clin Genitourin Cancer. 2024 Dec;22(6):102238. doi: 10.1016/j.clgc.2024.102238

Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Wang J, Zhou X, Gnanasakthy A, Taylor K, Yusuf A, Maher I, Jamotte A, Kang YK. Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer. ESMO gastrointestinal oncology. 2024 Dec;6. doi: 10.1016/j.esmogo.2024.100095

Leonard C, Unsworth H, Warttig S, Gildea L, Mordin M, Ling C. HTA considerations for large language models in healthcare. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S137. doi: 10.1016/j.jval.2024.03.730

Leonard C, Bhogal P, Menon AP, Ling C, Mordin M. HTA requirements for medical technologies in Spain. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S494. doi: 10.1016/j.jval.2024.10.2513

Khanji C, Nuabor W, Kim HK, Yubin SA, Kim R, Njue A. Systematic literature review of the economic burden of hemophilia A and B. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S629. doi: 10.1016/j.jval.2024.10.3157

Khanji C, Nuabor W, Kim HK, Yubin SA, Kim R, Njue A. Systematic literature review of the humanistic burden of hemophilia A and B. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S613. doi: 10.1016/j.jval.2024.10.3082

Yubin Sohn A, Khanji C, Nuabor W, Gould T, Kim HK, Barrows SM, Herbel B, Njue A. Effect of adherence to hemophilia drug therapy on outcomes: a systematic literature review. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S634. doi: 10.1016/j.jval.2024.10.3181

Khan S, Copley-Merriman K, Heyes A, Hawe E, Hartley L, Kallmes K. Qualitative and quantitative evidence synthesis strategies to support JCA and IRA submissions. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S382. doi: 10.1016/j.jval.2024.10.1970

Ling C, Hawe E, Stevenson A, Low EW. Giving voice to rare diseases during joint clinical assessment (JCA). Presented at the ISPOR Europe 2024; November 20, 2024. Barcelona, Spain.

Halsby K, Gildea L, Madhava H, Angulo FJ, Pilz A, Erber W, Moisi J, Schley K, Colosia A, Sellner J. Clinical manifestations and outcomes of tick-borne encephalitis: a systematic literature review. Ticks Tick Borne Dis. 2024 Nov 4;15(6):102407. doi: 10.1016/j.ttbdis.2024.102407

Broughton EI, Bektas M, Colosia A, Fernandez M, Kuper K, Al-Taie A, Kotb REM. Assessing the global economic burden of complicated urinary tract infections. Poster presented at the IDWeek 2024; October 18, 2024. Los Angeles, California.

Bagnato F, Mordin M, Greene N, Mahida S, Higuchi K, van Wingerden J. Evaluating association of chronic active lesions with disability in multiple sclerosis: a systematic literature review. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV. [abstract] J Manag Care Spec Pharm. 2024 Oct; 30(10-c):S155. Previously presented at the 10th Congress of the European Academy of Neurology.

Ayoub I, Bensink ME, Zhou X, Wang J, Gong W, Preciado P, Komers R, Inrig JK, Rheault MN, Tachtman H. Patient-reported outcomes in adults with FSGS: sparsentan vs. irbesartan. Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 23, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):281.

Wadhwani S, Bensink M, Peipert JD, Ayoub I, Preciado P, Garbinsky D, Wang J, Choi J, Bennett L, Gong W, Inrig J, Komers R. Patient-reported outcomes in the PROTECT clinical trial comparing sparsentan with irbesartan for IgA nephropathy. Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 23, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):723.

Gitomer BY, Chonchol M, Zhou X, Garbinsky D, Wang J, Nunna S, Fernandes AW, Oberdhan D. Kidney stone disease and progression risk in autosomal dominant polycystic kidney disease: a post hoc analysis of OVERTURE. Kidney360. 2024 Sep;5(9):1364-6. doi: 10.34067/KID.0000000000000524

Haug U, Morales DR, Ehrenstein V, Esen BO, Didelez V, Schafer W, Reinbold J, Martinez D, Garcia de Albeniz X, Gini R, Ryan O, Young J. Target trial emulation with real world evidence: regulatory grade pharmacoepidemiology in the SIGMA consortium. Presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.

Cid Royo A, Choi J, Plana E, Garcia Esteban R, Pajouheshnia R, Ryan O. A flexible open-source analytic pipeline for self-controlled analysis of real world data. Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.

Weibel D, De Luise C, Cid Royo A, Ryan O, Vaz T, Aguado J, Marsal J, Garcia de Albeniz Martinez X, Weinrib R, Yefimenko N, Pala E, Poblador-Plou B, Gimeno-Miguel A, Santos-Mejias A, Marconi E, Barbieri E, Stona L, Lysen T, Roy D, Hyeraci G, Girardi A, Lupattelli A, Desalegn AA, Villalobos F, Bissacco CA, Kendrick K, Garg R, Rubino H, Sturkenboom MCJM, Arana A. Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe. Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.

Khan S, Alkire J, Krumbach A, Talbird S. Best practices for adopting AMCP format version 5.0. Presented at RTI Webinar; August 6, 2024.

Booth G, Di Rosa A, Corcoran P, Hallisey C, Lucas A, Zarnegar R. Patient perspectives on the unwanted effects of multidisciplinary pain management programmes: a qualitative study. Clin Rehabil. 2024 Aug;38(8):1118-29. doi: 10.1177/02692155241254250

Taieb J, Fakih M, Salvatore L, Esaki T, Modest DP, Paez D, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Cremolini C, Wang J, Tran Q, Chao J, Chen Z, Pietrantonio F. Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study. Poster presented at the ESMO 2024 Gastrointestinal Cancers Annual Congress; June 26, 2024. Munich, Germany.

Gildea L, Arvin-Berod C, Heyes A, Heyerick A, Urdaniz E, Vainilovich Y, Trainor L, Densmore D. Evidence gap analysis of the burden of illness and treatment of thyroid eye disease. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S35. doi: 10.1016/j.jval.2024.03.184

Copley-Merriman K, Miller-Wilson LA, Costello J, Schwinn J, Edwards Y. Evidence gap analysis of the burden of illness and treatment of myasthenia gravis. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S384-5. doi: 10.1016/j.jval.2024.03.1792

Masaquel C, Miller-Wilson LA, D'Souza V, Schwinn J, Mina-Osorio P. Evidence gap analysis of the burden of disease in thyroid eye disease. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S389. doi: 10.1016/j.jval.2024.03.2461

Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. What is the medical technology HTA process in Japan? Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S284. doi: 10.1016/j.jval.2024.03.1554

Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. HTA requirements for medical technologies in Canada. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S286. doi: 10.1016/j.jval.2024.03.1564

Petit I, Eliasson L, Romero B, Patel C, Di Rosa A, Quinn J. Exploring the content and psychometric validity of clinical outcome assessments in renal cell carcinoma versus the patient reported symptoms and impacts. Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S309. doi: 10.1016/j.jval.2024.03.1955

Bagnato F, Mordin M, Greene N, Mahida S, Higuchi K, Wingerden J. Evaluating association of chronic active lesions with disability in multiple sclerosis: a systematic literature review. Poster presented at the 10th Congress of the European Academy of Neurology; June 29, 2024. Helenski, Finland. [abstract] Eur J Neurol. 2024 Jun; 31(Suppl 1).

Kluge F, Brand YE, Mico-Amigo ME, Bertuletti S, D'Ascanio I, Gazit E, Bonci T, Kirk C, Kuderle A, Palmerini L, Paraschiv-Ionescu A, Salis F, Soltani A, Ullrich M, Alcock L, Aminian K, Becker C, Brown P, Buekers J, Carsin AE, Caruso M, Caulfield B, Cereatti A, Chiari L, Echevarria C, Eskofier B, Evers J, Garcia-Aymerich J, Hache T, Hansen C, Hausdorff JM, Hiden H, Hume E, Keogh A, Koch S, Maetzler W, Megaritis D, Niessen M, Perlman O, Schwickert L, Scott K, Sharrack B, Singleton D, Vereijken B, Vogiatzis I, Yarnall A, Rochester L, Mazza C, Del Din S, Mueller A. Real-world gait detection using a wrist-worn inertial sensor: validation study. JMIR Form Res. 2024 May 1;8:e50035. doi: 10.2196/50035

Fernandez MM, Bektas M, Colosia A, Kuper K, Al-Taie A, Kotb R. Evidence gaps in the burden of complicated urinary tract infection (cUTI). Poster presented at the 34th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); April 27, 2024. Barcelona, Spain.

Tabberer M, Williamson N, Tatlock S, Gater A, Grimes R, Akinseye C, Neil D, Mahon-Smith A, Nelsen L. Qualitative interviews of patients with COPD and muscle weakness enrolled in a clinical trial evaluating a new anabolic treatment: patient perspectives of disease experience, trial participation and outcome assessments. J Patient Rep Outcomes. 2024 Apr 20;8(1):45. doi: 10.1186/s41687-024-00712-0

Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg C, Brown J, Dave V, Downey C, Shillington A, Katzenstein H, Kirker M, Hanson S, Liu F, Morris V, Bhanegaonkar A, Sonpavde G. Avelumab first-line maintenance (1LM) therapy for locally advanced/metastatic urothelial carcinoma (la/mUC): results from the realworld US PATRIOT-II study. Poster presented at the Academy of Managed Care Pharmacy (AMCP) 2024; April 15, 2024. New Orleans, LA. [abstract] J Manag Care Spec Pharm. 2024 Apr; 30(4-a):S123.